Introduction
The efficacy of early initiation of antiretroviral therapy (ART) in children is well established. 1 Several factors limit the scaling-up of paediatric ART, such as the lack of appropriate and palatable combinations, elevated costs and frequent stock shortage of drugs. Lallemant et al. 2 called for attention to the specificities of paediatric infection as they preclude direct extrapolation from data gathered in adults. Children have greater CD4 recovery capacity due to more active thymopoiesis, but have a higher rate of incomplete replication suppression. 3 In untreated adults, it was shown that HIV-DNA load, a proxy of the viral reservoir, is predictive of disease progression, independently of HIV-RNA and CD4 count. 4, 5 This predictive value exists at seroconversion regardless of the expression unit [copies/10 6 peripheral blood mononuclear cells (PBMCs), copies/mL]. 6 HIV-DNA load constitutes the only marker still detectable when replication is undetectable during ART and reflects the past HIV-RNA history. 7 -10 HIV-DNA decrease has been compared between adults initiating ART at the time of primary or at the time of chronic infection.
11
Data on HIV-DNA concentrations in children are scarce, and have mainly been collected from studies in northern countries, often with small sample sizes. HIV-DNA concentration is associated with clinical status, plasma HIV-RNA, CD4 counts, immune activation and HIV-specific immune responses. 12 -15 In children initiating ART, a higher baseline HIV-DNA is associated with a longer time to achieve HIV-1 RNA undetectability and with virological failure. 7 -10 The ongoing maturation of the immune system likely induces specific physiopathological mechanisms; studies on HIV reservoirs in children are thus needed. This study aimed at # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 3047 -3050 doi:10.1093/jac/dku274 Advance Access publication 17 July 2014 improving our knowledge on HIV-DNA in ART-naive children and dynamics during ART by assessing, for the first time, a biological parameter that has not been measured in routine care in a large African paediatric cohort.
Methods
All 121 children enrolled in the 'Programme Enfant Yopougon' who had cryopreserved PBMCs and plasma were included in the present study. The 'Programme Enfant Yopougon' was an observational cohort designed to document morbidity and mortality in HIV-1-infected children in Abidjan, Cô te d'Ivoire (ANRS1244), and to evaluate the impact of ART (ANRS1278). A total of 282 children were followed from October 2000 to September 2004 at the Yopougon hospital. The procedures and results of the cohort have been described elsewhere. 16 Briefly, children were eligible if they were .15 months. Criteria for initiation of ART were CDC stage C or CD4 ,15% of the total lymphocyte count. ART consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus nelfinavir/efavirenz at the physician's discretion. Children with CD4 ,20% received co-trimoxazole prophylaxis. The study protocol was approved by the Cô te d'Ivoire Ethics Committee on AIDS and written informed consent was obtained from the children's parents or caregivers.
Clinical examinations were performed every 3 months. CD4 cell count and HIV-RNA load were determined every 6 months at the Centre de Diagnostic et de Recherche sur le SIDA, Abidjan. CD4% was measured by flow cytometry (FACScan TM , Becton-Dickinson). Absolute CD4 counts were determined using an automated blood cell counter (MaxM Coulter, Beckman). HIV-RNA load was initially measured prospectively using the Quantiplex HIV-1-RNA 3.0 assay (Chiron) with a detection threshold of 250 copies/mL. From May 2003, HIV-RNA concentrations were determined using the Generic HIV Charge Virale test (Biocentric) with a detection threshold of 300 copies/mL.
HIV-DNA concentrations were retrospectively quantified in frozen PBMCs prepared with the same samples by RT -PCR (Generic HIV-DNA CELL, Biocentric) carried out retrospectively in the virology laboratory of the Necker Hospital, France. 17 The detection threshold was 70 copies/10 6 PBMCs. Results were reported as HIV-DNA log 10 copies/10 6 PBMCs (PBMC-HIV-DNA). Similarly to CD4 count and HIV-RNA, we also expressed results as copies per millilitre of blood (blood-HIV-DNA) using leucocyte, lymphocyte and monocyte counts, as previously described. 6 Correlations between continuous variables were performed using the Spearman non-parametric correlation method. To account for observation redundancy at the different visits, factors associated with the evolution of HIV-DNA loads during ART were investigated using mixed-model analysis. Given our sample size, only intercepts were allowed to vary between individuals. A multilevel model with fixed slope and random intercepts was estimated using the restricted maximum likelihood method. Variables with P, 0.25 in bivariate analysis were included in the model and a manual descending stepwise procedure was performed. The significance level was set at a ¼ 0.05; P values are two-sided. Analyses were performed using Stata 12.1 (StataCorp) and R (v2.13.0).
Results
One-hundred and twenty-one ART-naive children were included in the present study, including 65 (53.7%) boys; the median age at inclusion was 6 years (IQR: 3.5 -9.0) and 48 children (39.7%) were ≤5 years. Children were mostly at an advanced stage of HIV disease, with 46.6% and 20.3% of them presenting CDC stage B and CDC stage C, respectively. Baseline median CD4% was 11.2% (IQR: 5.5 -17. Before ART initiation, blood-HIV-DNA was independently associated with age [adjusted OR (aOR) ¼ 0.96, 95% CI ¼ 0.94 -0.99, P ¼ 0.002], CD4% (aOR ¼ 1.02, 95% CI ¼ 1.01 -1.03, P, 0.001) and HIV-RNA load (aOR ¼ 1.29, 95% CI ¼ 1.15 -1.46, P, 0.001). PBMC-HIV-DNA was not associated with age, but was associated independently with CD4% (aOR ¼ 1.02, 95% CI ¼ 0.1.01 -1.03, P,0.001 and aOR¼0.96, 95% CI¼0.95-0.97, P,0.001, respectively) and HIV-RNA load (aOR¼1.27, 95% CI¼1.16-1.40, P,0.001 and aOR¼1.21, 95% CI¼1.11-1.32, P,0.001, respectively).
Fifty-four children (44.6%) initiated ART during follow-up, at a median age of 6 years (IQR: 5-8.5) and were followed for a median duration of 36 months (IQR: 34-42). Forty children (74%) received a nelfinavir-based regimen while 14 received an efavirenz-based regimen. At ART initiation, median CD4% was 9.4% (IQR: 3.7 -12.0), median HIV-RNA load was 5.3 log copies/mL (IQR: 4.97 -5.73) and median HIV-DNA was 3.4 log 10 copies/10 6 PBMCs (IQR: 3.2-3.7) and 4.0 log 10 copies/mL (IQR: 3.7-4.3). After 24 months on ART, median PBMC-HIV-DNA concentration was 3.2 log 10 (IQR: 2.8 -3.5, n ¼ 26) and median blood-HIV-DNA concentration was 3.6 log 10 (IQR: 3.4-4.0, n¼25). (Figure 1b) .
In multivariate analysis, a low HIV-RNA load during follow-up was the only factor associated with a larger decrease in PBMC-HIV-DNA (b ¼ 0.11, 95% CI ¼ 0.08 -0.13, P, 0.001) and in blood-HIV-DNA (b¼0.12 per log 10 HIV-RNA, 95% CI¼0.09-0.15, P, 0.001). Gender, age, protease inhibitor (PI) regimen, CDC stage, CD4%, HIV-RNA load at inclusion or duration on ART were not significantly associated with the decrease in PBMC-HIV-DNA (Table 1) or blood-HIV-DNA.
Discussion
To our knowledge, this is the first study providing HIV-DNA concentrations in a large African paediatric cohort before and during ART. The baseline PBMC-HIV-DNA concentrations were similar to those described in acute HIV infection in adults [such as the French-PRIMO (3.25 log 10 ) 4 and the Ivoirian-PRIMO-CI (3.21 log 10 )
5 cohorts] and were higher than concentrations reported in long-term non-progressors (2.30 log 10 ) 18 and HIV controllers (1.30 log 10 ). 
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Before treatment, blood-HIV-DNA was found to decrease with age, but the total stock was increasing with age if the growth of the blood volume was accounted for (results not shown). In contrast, PBMC-HIV-DNA was associated with CD4% and HIV-RNA but was not related to age. These results highlight child specificities such as a higher thymic output of naive CD4 cells in contrast to expansion of memory T cells in adults, and age-dependent hyperlymphocytosis in contrast to fixed levels in adults. 20 Unfortunately our sample size did not allow us to assess the predictive value of HIV-DNA before treatment initiation for clinical and mortality outcomes.
This study showed that HIV-DNA concentrations decreased during efficient ART, i.e. when an undetectable HIV-RNA load was achieved. This finding is consistent with those published in adults and children. For instance, our results are similar to those of Saitoh et al., 12 which showed a rapid decline in HIV-DNA followed by a plateau reached at 18 months after ART initiation.
In our study, HIV-RNA load obtained during ART was the only factor correlated with the HIV-DNA decrease, whereas De Rossi et al. 8 found that a higher baseline HIV-RNA correlated with a higher HIV-DNA early decay.
Our study has limitations. Children were almost exclusively ≥2 years. The rapid progressors were likely not represented. The potency of the most commonly used regimen in our study (two NRTIs plus unboosted nelfinavir) might be expected to be less than that of efavirenz or other contemporary regimens, including boosted PI-based regimens. These might thus yield different results.
In conclusion, our study revealed evidence that ART lowered HIV-DNA concentrations in African treated children but underlines the difficulty of diminishing viral reservoir in real life in African children. In our era, a large number of HIV-infected children will reach adulthood, requiring strategies to diminish their viral reservoir and improve their outcomes. Our study underlines that a strong adherence is necessary to achieve an undetectable viral load and further reinforces that adherence support is also essential to diminish the viral reservoir.
